VanEck Associates
ARNA

VanEck Associates’s Arena Pharmaceuticals Inc ARNA Stock Holding History

VanEck Associates’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-58,772
Closed -$3.44M – 717
2013
Q4 		$3.44M Buy
58,772
+7,095
+14% +$371K 0.02% 268
2013
Q3 		$2.72M Buy
51,677
+409
+0.8% +$27.5K 0.01% 276
2013
Q2 		$3.95M Buy
+51,268
New +$4.19M 0.02% 240

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

VanEck Associates's ARNA Position: Q1 2014 in Review

VanEck Associates sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2014, closing a stake of 58,772 shares — an estimated $3.44M sold.

VanEck Associates first reported a position in ARNA in Q2 2013 and held it in 3 quarters. The position peaked at $3.95M in Q2 2013. 131 funds tracked by Wall St. Rank hold ARNA as of Q1 2014.

  • VanEck Associates reported no remaining Arena Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • VanEck Associates sold 58,772 Arena Pharmaceuticals Inc shares in Q1 2014, an estimated $3.44M.
  • VanEck Associates first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 3 quarters.
  • VanEck Associates's Arena Pharmaceuticals Inc position peaked at $3.95M in Q2 2013.
  • 131 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2014.

Based on VanEck Associates's 13F filing for Q1 2014, filed 8 May 2014.